Drug intelligence / Profile preview

AC5-GTM

Development stage: Preclinical
Lead developer: Arch Therapeutics
Modality: Peptides
Administration: Topical, Endoscopic

Overview

AC5-GTM is an investigational **self-assembling peptide** product from Arch Therapeutics being developed for gastrointestinal endoscopic procedures. It is part of the company's AC5 self-assembling barrier technology platform and is designed to form a local barrier or matrix at the treatment site, enabling **hemostasis**, tissue sealing, wound management, and creation of a durable **submucosal lift or cushion** during procedures such as endoscopic mucosal resection and endoscopic submucosal dissection. The formulation has been described as deliverable through standard endoscopic catheters and has been studied preclinically in porcine gastrointestinal models for endoscopic resection support and management of gastrointestinal bleeding.

Other names: AC5-GTMAC-5-GTMAC 5-GTM

Beyond the preview

Go deeper on AC5-GTM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC5-GTM.

Explore the full profile